U.S. markets closed
  • S&P 500

    4,513.04
    -53.96 (-1.18%)
     
  • Dow 30

    34,022.04
    -461.68 (-1.34%)
     
  • Nasdaq

    15,254.05
    -283.64 (-1.83%)
     
  • Russell 2000

    2,147.42
    -51.49 (-2.34%)
     
  • Crude Oil

    66.46
    +0.89 (+1.36%)
     
  • Gold

    1,782.00
    -2.30 (-0.13%)
     
  • Silver

    22.39
    +0.05 (+0.23%)
     
  • EUR/USD

    1.1320
    -0.0003 (-0.02%)
     
  • 10-Yr Bond

    1.4340
    -0.0090 (-0.62%)
     
  • GBP/USD

    1.3274
    -0.0003 (-0.03%)
     
  • USD/JPY

    112.8960
    +0.1160 (+0.10%)
     
  • BTC-USD

    56,767.54
    -784.83 (-1.36%)
     
  • CMC Crypto 200

    1,443.14
    -25.94 (-1.77%)
     
  • FTSE 100

    7,168.68
    +109.23 (+1.55%)
     
  • Nikkei 225

    27,904.37
    -31.25 (-0.11%)
     

New Strong Sell Stocks for August 24th

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

Here are five stocks added to the Zacks Rank #5 (Strong Sell) List today:

B&G Foods, Inc. BGS manufactures, sells, and distributes a portfolio of shelf-stable and frozen foods, and household products. The Zacks Consensus Estimate for its current year earnings has been revised 3.7% downward over the last 30 days.

Fathom Holdings Inc. FTHM provides cloud-based real estate brokerage services. The Zacks Consensus Estimate for its current year earnings has been revised more than 100% downward over the last 30 days.

Intellia Therapeutics, Inc. NTLA is a genome editing company, focuses on the development of therapeutics. The Zacks Consensus Estimate for its current year earnings has been revised 21.9% downward over the last 30 days.

Level One Bancorp, Inc. LEVL provides business and consumer financial services. The Zacks Consensus Estimate for its current year earnings has been revised 9.9% downward over the last 30 days.

Eloxx Pharmaceuticals, Inc. ELOX is a clinical-stage biopharmaceutical company. The Zacks Consensus Estimate for its current year earnings has been revised 79.3% downward over the last 30 days.

View the entire Zacks Rank #5 List.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
B&G Foods, Inc. (BGS) : Free Stock Analysis Report
 
Intellia Therapeutics, Inc. (NTLA) : Free Stock Analysis Report
 
Senesco Technologies Inc. (ELOX) : Free Stock Analysis Report
 
Level One Bancorp, Inc. (LEVL) : Free Stock Analysis Report
 
Fathom Holdings Inc. (FTHM) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research